Organogenesis Begins FDA Rolling Review for ReNu Biologics License Application
I'm PortAI, I can summarize articles.
Organogenesis Holdings Inc. has started a rolling submission of a Biologics License Application to the FDA for ReNu®, aimed at treating knee osteoarthritis. The submission is expected to be completed by mid-2026. ReNu has received the FDA’s RMAT designation. The news was originally published by Organogenesis via GlobeNewswire on December 23, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments